Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Substantial Shareholding

19 Jun 2008 17:26

RNS Number : 1421X
ReGen Therapeutics PLC
19 June 2008
 
 
19th June 2008
 
REGEN THERAPEUTICS PLC
(“ReGen” or the “Company”; Ticker: (RGT))
 
 
TR-1(i): NOTIFICATION OF MAJOR INTEREST IN SHARES
 
 
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached (ii):
 
ReGen Therapeutics Plc
 
2. Reason for the notification:
 
An acquisition or disposal of voting rights
 
3. Full name of person(s) subject to the notification obligation (iii):
 
Andrew Clement Wilson
 
4. Full name of shareholder(s) (if difference from 3):
 
As above
 
5. Date of the transaction and date on which the threshold is crossed or reached (v):
 
18 June 2008
 
6. Date on which issued notified:
 
19 June 2008
 
7. Threshold(s) that is/are crossed or reached:
 
13%
8. Notified details
 
A: Voting rights attached to shares
 
Class/type of share if possible using the ISIN Code GB00B28XMY25
 
Situation Previous to the triggering transaction (vi) –
Number of Shares 1,477,000
Number of Voting Rights (viii) 1,477,000
 
Resulting situation after the triggering transaction (viii) –
Number of Shares 1,495,000
Number of Voting Rights – Direct (x) 1,495,000
Number of Voting Rights – Indirect (xi) N/A
% of voting rights – Direct 13.02%
% of voting rights – Indirect N/A
B: Financial Instruments
Resulting situation after the triggering transaction (xii)
 
Type of financial instrument N/A
 
Expiration date (xiii) N/A
 
Exercise/Conversion Period/Date (xiv) N/A
 
Number of voting rights that may be acquired if the
instrument is exercised/converted N/A
 
% of voting rights N/A
Total (A+B)
 
Number of voting rights 1,495,000
 
% of voting rights 13.02
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable (xv):
 
Shares are held in own name
 
Proxy Voting:
 
10. Name of the proxy holder: N/A
 
11. Number of voting rights proxy holder will cease to hold: N/A
 
12. Date on which proxy holder will cease to hold voting rights: N/A
 
13. Additional information: N/A
 
14. Contact name: N/A
 
15. Contact telephone number: N/A
 
 
For further information:
 
Percy Lomax
ReGen Therapeutics Plc
Tel: +44 (0) 207 153 4920
 
Roland Cornish / Felicity Geidt
Beaumont Cornish Limited
Tel: +44(0) 207 628 3396

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFKCKDABKDCAD
Date   Source Headline
20th Oct 20212:29 pmRNSScheme of arrangement
20th Oct 20212:00 pmRNSPrice Monitoring Extension
20th Oct 20217:00 amRNSDirector/PDMR Shareholding
19th Oct 20212:01 pmRNSCapital Reorganisation
6th Oct 20213:19 pmRNSDirector/PDMR Shareholding
5th Oct 20217:00 amRNSDirector/PDMR Dealing
4th Oct 20218:06 amRNSPDMR Dealing
28th Sep 20217:00 amRNSDirector/PDMR Shareholding
27th Sep 20215:16 pmRNSResult of Meeting
27th Sep 20215:11 pmRNSResult of Meeting
24th Sep 20215:49 pmRNSHalf-year Report
20th Sep 202111:05 amRNSSecond Price Monitoring Extn
20th Sep 202111:00 amRNSPrice Monitoring Extension
20th Sep 20219:05 amRNSSecond Price Monitoring Extn
20th Sep 20219:00 amRNSPrice Monitoring Extension
7th Sep 20216:00 pmRNSChange of Registered Office
7th Sep 20217:00 amRNSTLSA to Host Call to Discuss Exclusive License
3rd Sep 20215:00 pmRNSPosting of Scheme Document and Notice of Meetings
3rd Sep 20217:00 amRNSPosting of Scheme Document and Notice of Meetings
2nd Sep 202111:05 amRNSSecond Price Monitoring Extn
2nd Sep 202111:00 amRNSPrice Monitoring Extension
2nd Sep 20217:00 amRNSLicense Agreement to Evaluate Foralumab with CAR T
20th Aug 20217:00 amRNSTiLS files scheme for a corporate reorganisation
17th Aug 20217:00 amRNSArticle Publication on Foralumab in COVID Patients
16th Aug 20216:11 pmRNSTLSA to Present at the Q3 Virtual Investor Summit
3rd Aug 20214:41 pmRNSSecond Price Monitoring Extn
3rd Aug 20214:35 pmRNSPrice Monitoring Extension
8th Jul 202112:19 pmRNSADS Ex-Dividend Date Scheduled for July, 09 2021
2nd Jul 202112:30 pmRNSDistribution Dates for shares and ADRs in Accustem
2nd Jul 202112:30 pmRNSDistribution Dates: shares and ADRs in Accustem
30th Jun 202111:36 amRNSDr Howard Weiner on Bloomberg at 1.50pm ET today
25th Jun 202110:40 amRNSResult of Annual General Meeting
23rd Jun 20217:00 amRNSP2 Trial with foralumab on Severe COVID19 Patients
21st Jun 20217:08 amRNSAppointment of VP of Regulatory Affairs
17th Jun 20217:00 amRNSTiziana Applies for Grant from UK-CTAP
2nd Jun 20217:00 amRNSNotice of AGM
26th May 20217:00 amRNSSignificant Immunomodulation effects on Biomarkers
25th May 20217:00 amRNSTrial Initiation in a SPMS Patient with Foralumab
21st May 20217:00 amRNSDirector/PDMR Dealing
18th May 202112:18 pmRNSAmended - Final Results
18th May 202111:08 amRNSFinal Results
7th May 20217:00 amRNSTLSA interview on Bloomberg TV on 8th May 2021
5th May 20217:45 amRNSTLSA Strategic Initiative with Takanawa Japan K.K.
27th Apr 20217:00 amRNSB. Riley Virtual Neuroscience Investor Conference
13th Apr 202112:00 pmRNSTiziana Announces Plans to List Accustem in US
30th Mar 20214:41 pmRNSSecond Price Monitoring Extn
30th Mar 20214:36 pmRNSPrice Monitoring Extension
30th Mar 20212:05 pmRNSSecond Price Monitoring Extn
30th Mar 20212:00 pmRNSPrice Monitoring Extension
30th Mar 20211:00 pmRNSFDA Allows Foralumab Treatment for a SPMS Patient

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.